Wanbury ropes in Prakash Venkatraman as President of API business

Published On 2024-08-16 10:23 GMT   |   Update On 2024-08-16 10:23 GMT

Mumbai: Wanbury Limited has announced the appointment of Prakash Venkatraman as President of the API business. With a stellar career spanning over three decades, Venkatraman has a wealth of experience in API operations, P&L management, and business strategy.

Venkatraman most recently served as Senior Vice President of the API business at Shilpa Pharma Lifesciences for over 3 years. In this role, he spearheaded the API division, driving growth and delivering on revenue and EBITDA targets.

Advertisement

Previously, Venkatraman led Global Sales and Business Development for Sun Pharma's API division, a $175 million business, as Senior Vice President for over 2 years. Venkatraman spent 8 years at Jubilant Life Sciences as Senior Vice President of the API business. He led a $105 million division, establishing Jubilant as a global leader in specific molecules and expanding capacity to meet surging demand.

Read also: EMA validates submission of Marketing Authorization Application for skin cancer treatment Nidlegy: Sun Pharma, Philogen

Venkatraman's career also includes senior leadership roles at Wockhardt, Ranbaxy, and Kopran, where he consistently delivered on organizational objectives.

Venkatraman holds a Bachelor's degree in Chemical Engineering and a Master's degree in Management Studies from Mumbai University. 

Read also: Shilpa Medicare successfully completes Phase 1 clinical trial for Recombinant Human Albumin 20%

Wanbury Limited has a presence in API global market and domestic branded Formulation. Wanbury strength lies in Active Pharmaceutical Ingredient (API) Sales & Marketing in over 50 countries and Pan-India Formulation presence. The Company has a basket of over 13 API products. It has the larger customer base in Europe & US for Tramadol & Setraline (API).The Company has two US-FDA approved multi-product API facilities and one plant under operation for semi-regulated markets. It has pan-India presence in ethical formulations with a portfolio of close to 70 brands.

Read also: Sun Pharmaceutical Industry gets CDSCO Panel nod to study Fexuprazan HCL tablet for erosive esophagitis

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News